BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) amgen.com ↗
2024-06-14
Amgen
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE amgen.com ↗
2023-06-21
Amgen
FDA GRANTS FULL APPROVAL FOR BLINCYTO® (BLINATUMOMAB) TO TREAT MINIMAL RESIDUAL DISEASE-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA amgen.com ↗
2022-12-13
Amgen
BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) amgen.com ↗
2021-03-02
Amgen
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free Survival Compared With Consolidation Chemotherapy In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia amgen.com ↗
2019-09-24
Amgen
Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia amgen.com ↗
2019-06-16
Amgen
Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019 amgen.com ↗
2019-01-22
Amgen
European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2018-11-16
Amgen
Amgen Receives CHMP Positive Opinion To Expand Use Of BLINCYTO® (Blinatumomab) In Patients With Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2018-09-25
Amgen
BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia amgen.com ↗
2018-08-29
Amgen
European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2018-06-19
Amgen
Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label amgen.com ↗
2018-03-29
Amgen
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children amgen.com ↗
2018-02-14
Amgen
Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO® (blinatumomab) amgen.com ↗
2017-07-11
Amgen
FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children amgen.com ↗
2017-03-29
Amgen
Journal Of Clinical Oncology Publishes Data On BLINCYTO® (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2017-03-29
Amgen
FDA Grants Priority Review For Amgen's BLINCYTO® (blinatumomab) Supplemental Biologics License Application amgen.com ↗
2017-03-01
Amgen
BLINCYTO® (blinatumomab) Significantly Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Compared To Chemotherapy amgen.com ↗
2017-02-14
Amgen
Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2016-09-01
Amgen
FDA Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2016-06-10
Amgen
BLINCYTO® (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2016-05-03
Amgen
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) amgen.com ↗
Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2015-12-07
Amgen
Amgen Presents Data From Three Trials Evaluating BLINCYTO® (blinatumomab) In Acute Lymphoblastic Leukemia At ASH 2015 amgen.com ↗
2015-11-24
Amgen
European Commission Approves Amgen's BLINCYTO® (blinatumomab) for the Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia amgen.com ↗
2015-07-16
Amgen
Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
2014-12-09
Amgen
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia amgen.com ↗
2014-12-06
Amgen
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease amgen.com ↗
2014-12-03
Amgen
FDA Approves BLINCYTO™ (Blinatumomab) Immunotherapy for the Treatment of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia amgen.com ↗
Evidence & citations 13 cited values
Every value below carries the sentence it was read from.
165 sources stand behind the page.
Field
Value
Cited text
Known as
Blinatumomab
“For high-risk patients, a combination of immunotherapy (blinatumomab - a bispecific CD3 / CD19 T-cell activator) and HSCT in the first remission was chosen.” NCT05029531 ↗162
“Multiple studies have reported that blinatumomab achieves complete remission rates of 33-50% in refractory/relapsed Ph-negative B-ALL.” NCT07105579 ↗
“Blinatumomab is a CD19×CD3 bispecific T-cell engager (BiTE) administered via intravenous infusion.” NCT07689149 ↗
“Blinatumomab will be given intravenously up to five cycles.” NCT05931757 ↗
“Blinatumomab, Dasatinib, Methotrexate, and Dexamethasone” NCT06773936 ↗
“Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗
Known as
Blina
“The induction therapy is a combination of Blinatumomab(Blina), Vindesine(VDS), Cyclophosphamide(CTX) and Dexamethasone(DXM).” NCT06742515 ↗1
“All LR-B-ALL patients will be treated with 14 days of blinatumomab (Blina-14) as early intensification to replace CAT+” NCT06882057 ↗
Known as
Blincyto
“Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE®) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell...” NCT03931642 ↗4
“Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗
“Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗
Known as
MEDI 538
“Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)” NCT00676871 ↗2
“Blinatumomab (BLINCYTO , AMG 103, formerly also known as MT103 or bscCD19xCD3) is a novel single chain antibody construct in the class of the bispecific T-cell engager (BiTE®).” NCT04827745 ↗
Known as
NSC# 765986
“A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy” NCT03914625 ↗
Action
Deplete
“resulting in T-cell activation and a cytotoxic T-cell response against CD19+ cells.” NCT00274742 ↗